DRTS ALPHA TAU MEDICAL LTD.

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-person at the Jefferies Radiopharma Innovation Summit in New York City on Monday, April 3rd, 2023.

Event:Jefferies Radiopharma Innovation Summit
Date:Monday, April 3rd, 2023
Time:3:30-4:00 PM ET
Location:Jefferies, NY, New York

Raphi Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.

About Alpha Tau Medical, Ltd.



Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Investor Relations Contact:



EN
29/03/2023

Underlying

DRTSALPHA TAU MEDICAL LTD.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TAU MEDICAL LTD.

 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides...

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot studies, positioned for imminent patient treatment initiation during the remainder of 2025 - - Secured $36.9 million through a strategic equity offering at market price from Oramed, while concurrently entering into a strategic IR/PR alliance - - Cash, ca...

August 11, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau to Present at Jefferies Global Healthcare Conference

Alpha Tau to Present at Jefferies Global Healthcare Conference JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025. Event:Jefferies Global Healthcare ConferenceFormat:PresentationDate:June 5, 2025Time:1:25 – 1:55PM ETLocation:New York, NY   Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies repres...

May 28, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces First Quarter 2025 Financial Results and Provides ...

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -       - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in ...

May 19, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Direct...

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: , ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company’s Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. “Nadav is a fantasti...

May 12, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau to Participate in May Investor Conferences

Alpha Tau to Participate in May Investor Conferences JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025. Event:H.C. Wainwright 3rd Annual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2025Time:3:30 – 4:00PM ETLocation:New York, NY Event:Lytham Partners Spring 2025 Investor ConferenceFormat:1x1 MeetingsDate:May 29, 2025Locati...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch